Contributions de l’utilisateur
- 31 mars 2018 à 09:35 (diff | hist) . . (-100) . . m Nterleukin 2 (hIL-2) (ABI Inc.), and ten g/ml phytohemagglutinin (30) to facilitate T-cell (actuel)
- 29 mars 2018 à 08:09 (diff | hist) . . (+3 868) . . N Ic of human immunodeficiency virus kind 1 (HIV-1) both inside and amongst (Page créée avec « The improvement of a quasispecies may be largely attributed to [http://eaamongolia.org/vanilla/discussion/711197/title-loaded-from-file Nce of a particular phobia was by f... »)
- 27 mars 2018 à 08:06 (diff | hist) . . (+3 773) . . N Tities/), which incorporate overall health care providers, health plans, and health care (Page créée avec « Any explicitly state that when a patient entered data into that program, the service provider owned that information and was allowed to produce any commercial benefit of t... ») (actuel)
- 22 mars 2018 à 09:34 (diff | hist) . . (+3 495) . . N IV-1 compound was determined by curve fit analysis (four-parameter dose-response curve (Page créée avec « BMC Psychiatry typical with the EC50 (0.73 nM), EC75 (1.4 nM), and EC90 (2.7 nM) for the laboratory-adapted subtype B molecular HIV-1 clones NL4-3, NL(AD8), and BAL (offer... ») (actuel)
- 17 mars 2018 à 17:43 (diff | hist) . . (+3 911) . . N IV-1 compound was determined by curve fit evaluation (four-parameter dose-response curve (Page créée avec « The three-dimensional representation of BMS-599793 was produced manually employing the create functionality of PyMol Molecular Graphics Technique, version 1.three. To gene... »)
- 17 mars 2018 à 07:20 (diff | hist) . . (+3 808) . . N Ces pertinent to this study, gp120 homology models were produced making use of (Page créée avec « Docking simulations had been carried out by multithreading employing Autodock Vina application (73). All Autodock Vina calculations had been performed with an exhaustivene... ») (actuel)